The recent approval of a new schizophrenia drug opens the door for newer, safer, and more efficacious treatment options without the unwanted side-effects.
With the the psychedelic field dynamic and rapidly changing, Monash’s pioneering Clinical Psychedelic Lab has a vision to make a meaningful difference in mental healthcare.
The technology to link human brains with computers is developing quickly – but the path ahead is full of challenges.
The drug donanemab is being hailed as a turning point in the fight against Alzheimer’s, following a global trial that confirms it can slow cognitive decline.
This week, Monash University's “What Happens Next?” podcast investigates how making reproductive healthcare inaccessible hurts us all.
As Alzheimer’s cases grow, scientists have been deep in debate over its causes. Now, with treatments are on the horizon, the new race is to ready the health system.
It’s almost comically hypocritical to argue that the Therapeutic Goods Administration needs to ‘loosen up’ in the context of the COVID-19 pandemic.
For only the second time in 60 years, a drug has been approved for the treatment of lupus, a debilitating form of rheumatic disease.
We'll struggle to find a vaccine that works perfectly for people who need it most, despite what the headlines say is coming in 2021.
Early analysis suggests Pfizer's COVID-19 vaccine has an efficacy of more than 90%, but more data is still needed.
With the COVID-19 landscape changing daily, an Australian team of researchers and clinicians has come together to deliver up-to-the-minute, evidence-based guidance for the care of people with the disease.
Dummy text
